Poster
T-DXd
ESMO Gyn 2025 | June 19-21, 2025
Ovarian Cancer
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO-01)
Antonio González-Martín
Mini-Oral
R-DXd
ESMO Gyn 2025 | June 19-21, 2025
Ovarian Cancer
Raludotatug deruxtecan (R-DXd) monotherapy in patients with heavily pretreated platinum-sensitive ovarian cancer: Subgroup analysis of a Phase 1 study
Kathleen Moore
Poster
R-DXd
ESMO Gyn 2025 | June 19-21, 2025
Ovarian Cancer
REJOICE-Ovarian02: A phase 1b/2 study of raludotatug deruxtecan (R-DXd) with other anticancer agents in participants with relapsed ovarian cancer after platinum-based chemotherapy
Ana Oaknin